Navigation Links
Molecular fingerprint discovered that may improve outcomes for head and neck cancer patients

January 23, 2012 (BRONX, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening. The biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This discovery could become a component of a new test to guide how aggressively those with head and neck tumors should be treated. The findings were published online January 9 in the American Journal of Pathology.

"Previous efforts to identify biomarkers for guiding treatment of head and neck cancer have not developed anything clinically useful for patients," said Geoffrey Childs, Ph.D., professor of pathology at Einstein and co-senior author of the paper.

Head and neck cancers, the sixth most common malignancy among men worldwide, most often affect the mouth, back of the throat and larynx (voice box). Smoking and alcohol use are major risk factors. Only half of patients are still alive more than five years after diagnosisa survival rate that hasn't changed in 40 years.

In their study, researchers took tissue samples from tumors and nearby healthy tissue of 123 head and neck cancer patients at Montefiore and measured levels of 736 members of a class of RNA molecules known as microRNAs. Certain members of this family of RNAs, which regulate protein abundance in cells, are abnormally expressed in head and neck cancers as well as every other malignant cell type yet examined. Of all the microRNAs measured, one in particular miR-375 stood out for being the most down-regulated (i.e., expressed at low levels) in head and neck tumors compared with its levels in adjacent normal tissue.

The researchers ranked these 123 patients according to how extreme the difference was between the miR-375 in their tumor and in adjacent normal tissue, with that difference expressed as the ratio "miR-375 level in patient's tumor tissue divided by miR-375 level in patient's normal tissue." All patients were then followed throughout the course of their illness.

MiR-375 proved to be a highly useful biomarker for predicting disease outcome. The patients for whom the difference between their tumor and normal-tissue miR-375 levels was most extreme (i.e., the one-fourth of patients with the lowest ratios) were nearly 13 times more likely to die or 9 times more likely to experience distant spread (metastasis) of their cancer compared to patients with higher miR-375 ratios.

"As as a result of our study," Dr. Childs noted, "we hope that miR-375 will become part of a laboratory test to determine which patients have potentially lethal tumors and therefore should be treated aggressively following initial diagnosis. Our entire head and neck cancer group is working to identify and refine additional biomarkers to create a useful clinical test or 'personalized genetic signature' to help individual patients get the best possible treatment."


Contact: Kimberly Newman
Albert Einstein College of Medicine

Related medicine news :

1. Toronto researchers obtain detailed molecular signature for Tankyrase
2. Unlocking the genetic and molecular mystery of soft-tissue sarcoma
3. A new molecular mechanism in breast cancer development
4. Molecular link between diabetes and cancer described
5. AACR-NCI-EORTC to hold molecular targets meeting in San Francisco
6. Nobel Laureate Bruce Beutler on molecular sensors as a trigger for autoimmune disease
7. Biodesign researchers to develop new reagent pipeline for molecular medicine
8. Molecular depth profiling modeled using buckyballs and low-energy argon
9. New equation predicts molecular forces in hydrophobic interactions
10. AACR hosts molecular targets and cancer therapeutics conference
11. Researchers identify potential molecular target to prevent growth of cancer cells
Post Your Comments:
(Date:12/2/2015)... , ... December 02, 2015 , ... ... for original 1966 Grateful Dead Santa Venetia Armory boxing style concert posters. These ... supporting the Bay Area music scene in the 1960s. The concert was held ...
(Date:12/1/2015)... ... December 02, 2015 , ... The ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting 850,000 members and over ...
(Date:12/1/2015)... ... December 02, 2015 , ... Ruth Pearson was struggling. She had been ... walk without assistance and quickly losing hope of recovering her former life, Pearson was ... Pearson was attending a women’s retreat when she experienced a particularly impactful worship service. ...
(Date:12/1/2015)... ... December 02, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting 850,000 members and, over 200 operating Local ...
(Date:12/1/2015)... ... December 02, 2015 , ... ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting 850,000 members and over 200 ...
Breaking Medicine News(10 mins):
(Date:12/2/2015)... and BOSTON and AMSTERDAM ... global contract research organization (CRO) focusing in oncology, ... it has acquired Clinquest, Inc. (US) and Clinquest ... (Clinquest) from Clinquest Group BV. With offices in ... Boston, MA ; Clinquest provides ...
(Date:12/2/2015)... TOWN , Dec. 2, 2015 ... availability of child-friendly tuberculosis (TB) medicines in the ... to meet the dosage guidelines set by the ... dispersible and palatable, simple to administer and affordable. ... of a project largely funded by UNITAID. ...
(Date:12/2/2015)... , December 2, 2015 ... the addition of the  "Global Laparotomy ... offering.  --> ) ... "Global Laparotomy Sponge Market 2015-2019"  report ... Research and Markets ( ) has ...
Breaking Medicine Technology: